- Home
- WLKP vs ENGN Comparison
WLKP vs ENGN Comparison
Compare WLKP & ENGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | WLKP | ENGN |
|---|---|---|
| Founded | 2014 | 1999 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Major Chemicals | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 700.7M | 605.5M |
| IPO Year | 2014 | N/A |
Fundamental Metrics
Financial Performance| Metric | WLKP | ENGN |
|---|---|---|
| Price | $20.35 | $8.94 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $22.71 |
| AVG Volume (30 Days) | 66.5K | ★ 202.6K |
| Earning Date | 02-23-2026 | 12-22-2025 |
| Dividend Yield | ★ 9.28% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.39 | N/A |
| Revenue | ★ $1,133,706,000.00 | N/A |
| Revenue This Year | $3.88 | N/A |
| Revenue Next Year | $12.71 | N/A |
| P/E Ratio | $14.57 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $17.75 | $2.65 |
| 52 Week High | $25.04 | $11.14 |
Technical Indicators
Market Signals| Indicator | WLKP | ENGN |
|---|---|---|
| Relative Strength Index (RSI) | 72.21 | 56.78 |
| Support Level | $19.07 | $8.16 |
| Resistance Level | $19.98 | $9.20 |
| Average True Range (ATR) | 0.44 | 0.63 |
| MACD | 0.17 | -0.06 |
| Stochastic Oscillator | 99.18 | 47.52 |
Price Performance
Historical ComparisonAbout WLKP Westlake Chemical Partners LP
Westlake Chemical Partners LP is a part of the chemical industry in the United States. Its operations are conducted through OpCo, it acquires and develops ethylene production facilities, which convert ethane into ethylene. OpCo sells ethylene and its co-products such as propylene, crude butadiene, pyrolysis gasoline, and hydrogen to Westlake and other customers located in the United States. Its assets include three ethylene production facilities in Calvert City, Kentucky, and Lake Charles, Louisiana.
About ENGN enGene Holdings Inc.
enGene Holdings Inc is a clinical-stage biotechnology company mainstreaming genetic medicine through the delivery of therapeutics to mucosal tissues and other organs, with the goal of creating new ways to address diseases with high clinical needs, beginning with non-muscle invasive bladder cancer (NMIBC). The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.